Skip to content

Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00029

Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00029

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04079842
Enrollment
29
Registered
2019-09-06
Start date
2019-08-20
Completion date
2019-08-28
Last updated
2022-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

ORi is a unitless index that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to PaO2 values of 100mmHg and below, and an ORi of 1.00 corresponds to PaO2 values of 200mmHg and above. In this study, the PaO2 is varied by controlling the concentration of oxygen the study volunteer breathes. Changes in ORi values are analyzed by comparing it to corresponding changes in PaO2 measurements from blood samples.

Interventions

Noninvasive pulse oximeter sensor

Sponsors

Masimo Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall. * Hemoglobin value is greater than or equal to 11 g/dL. * Baseline heart rate ≥ 45 bpm and ≤ 85 bpm. * Carbon monoxide (CO) value ≤ 2.0% fractional carboxyhemoglobin (FCOHb). * Subject has a physical status of ASA I or II (American Society of Anesthesiology Class 1; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) as it applies to the systemic disease portion of the classification. * Blood Pressure: (Systolic Blood Pressure ≤ 140 mmHg and ≥ 90 mmHg, Diastolic Blood Pressure ≤ 90 mmHg and ≥ 50 mmHg), and if blood pressure is lower than 100/60 subject passes an orthostatic blood pressure test * Subject is able to read and communicate in English and understands the study and risks involved.

Exclusion criteria

* Subject is pregnant. * Subject has a BMI \> 35 and has been classified as morbidly obese or at an increased risk for participation by a medical professional. * Subject has a history of fainting (vasovagal), blacking out or losing consciousness during or after a blood draw, or has a fear of blood draws. * Subject smokes one pack of cigarettes or more in one week, and/or the equivalent of e-cigarette liquid, and smokers are not being recruited as indicated in the CSRF. * Subject has open wounds, inflamed tattoos or piercings and/or any visible healing wounds that a medical professional renders them at an increased risk for participation (per physician discretion). * Subject has known drug or alcohol abuse or uses recreational drugs. * Subject experiences frequent or severe headaches and/or migraine headaches, migraine auras, altitude sickness, and/or headaches accompanied by visual changes or sensitivity to light or sound. * Subject has experienced a concussion or head injury with loss of consciousness within the past 12 months. * Subject has any history of a stroke, myocardial infarction, seizures or heart attack. * Subject who has taken anticoagulant medications within the last 30 days (excluding nonsteroidal anti-inflammatory drugs (NSAIDS). * Subject has donated blood within the past 4 weeks. * Subject has any chronic bleeding disorder (i.e. hemophilia) * Subject has any symptomatic cardiac dysrhythmia (i.e. atrial fibrillation) and has not received clearance from their physician to participate. * Subject has Wolff-Parkinson-White Syndrome or Stokes - Adams syndrome. * Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder, Multiple Sclerosis, Huntington's disease) that interferes with the subjects' level of consciousness. * Subject has taken opioid pain medication within 24 hours of start of study. * Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu, Malaria, Measles, etc.). * Subject is taking medications known to treat any type of infectious disease (per physician discretion). * Subject has either signs or history of peripheral ischemia or carpal tunnel syndrome. * Subject has had invasive surgery within the past year- including but not limited to major dental surgery, appendix, plastic surgery (per physician discretion). * Subject has had invasive surgery within the past year- including but not limited to gallbladder, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery. * Subject has symptoms of congestion, head cold, flu or other illnesses. * Subject is claustrophobic and/or has generalized anxiety disorder. * Subject has been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the past 12 months. * Subject has any cancer or history of cancer (not including skin cancer), per physician discretion. * Subject has chronic unresolved asthma, lung disease (including COPD) and/or respiratory disease. * Subject is allergic to lidocaine, latex, adhesives, or plastic. * Subject has a heart condition, insulin-dependent Diabetes, or uncontrolled hypertension. * Subject has delivered vaginally, has had a pregnancy terminated, a miscarriage with hospitalization, or had a C-section within the past 6 months. * Subject intends to participate in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle, tennis) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study that involved an arterial line. * Subject has any medical condition which in the judgement of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator/study staff).

Design outcomes

Primary

MeasureTime frameDescription
Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.1 to 5 hours per subjectORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.
Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values1-5 hours per subjectORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.
Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.1 to 5 hours per subjectORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.

Countries

United States

Participant flow

Pre-assignment details

Of of the 54 enrolled participants, 29 met inclusion criteria and proceeded to the study. The remainder of the enrolled participants include screen failures and subjects that did not proceed due to time constraints.

Participants by arm

ArmCount
INVSENSOR00029
All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor INVSENSOR00029: Noninvasive pulse oximeter sensor
26
Total26

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyRequest of subject2
Overall StudyUnable to draw Arterial samples1

Baseline characteristics

CharacteristicINVSENSOR00029
Age, Customized
18 to 50 years old
26 Participants
Age, Customized
<18 years old
0 Participants
Age, Customized
>50 years old
0 Participants
Race/Ethnicity, Customized
Asian or Pacific Islander
4 Participants
Race/Ethnicity, Customized
Black/Dark Skinned/African American
7 Participants
Race/Ethnicity, Customized
Caucasian
6 Participants
Race/Ethnicity, Customized
Hispanic
8 Participants
Race/Ethnicity, Customized
Middle Eastern
1 Participants
Sex: Female, Male
Female
7 Participants
Sex: Female, Male
Male
19 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 26
other
Total, other adverse events
0 / 26
serious
Total, serious adverse events
0 / 26

Outcome results

Primary

Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values

ORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.

Time frame: 1-5 hours per subject

ArmMeasureGroupValue (NUMBER)
INVSENSOR00029Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 ValuesPaO2 Threshold: 110 mmHg99.4 percentage of accuracy
INVSENSOR00029Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 ValuesPaO2 Threshold: 150 mmHg89.74 percentage of accuracy
INVSENSOR00029Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 ValuesPaO2 Threshold: 190 mmHg89.86 percentage of accuracy
Primary

Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.

ORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.

Time frame: 1 to 5 hours per subject

ArmMeasureGroupValue (NUMBER)
INVSENSOR00029Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.PaO2 Threshold: 110 mmHgNA percentage of true positives
INVSENSOR00029Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.PaO2 Threshold: 150 mmHg94.30 percentage of true positives
INVSENSOR00029Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.PaO2 Threshold: 190 mmHg90.18 percentage of true positives
Primary

Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.

ORi is an index value without a unit and ORi does not directly measure PaO2. Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.

Time frame: 1 to 5 hours per subject

ArmMeasureGroupValue (NUMBER)
INVSENSOR00029Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.PaO2 Threshold: 110 mmHg99.39 percentage of true negatives
INVSENSOR00029Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.PaO2 Threshold: 150 mmHg83.48 percentage of true negatives
INVSENSOR00029Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.PaO2 Threshold: 190 mmHgNA percentage of true negatives

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026